Skip to main content

Table 1 The details of individual study

From: Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia

Study Therapy in experimental group Therapy in control group Sample size method Follow-up time (month) Dosage (mg/mg) Main inclusion criteria Main exclusion criteria
experimental control
Hong et al. (2010) [20] tamsulosin plus dutasteride tamsulosin 37 37 Oral 12 0 .2mg + 0 .5mg/0 .2mg Men aged 45–75 years with moderate to severe symptomatic BPH, IPSS > 7, Qmax < 15 mL/s, PV ≥30 mL on TRUS, PSA < 10 ng/mL. Previous treatment with a 5ARI or other hormonal drugs, endocrine disorder including diabetes mellitus, previous prostatic surgery within the past year.
Joo et al. (2012) [21] tamsulosin plus dutasteride tamsulosin 98 95 Oral 12 0 .2mg + 0 .5mg/0 .2mg Age ≥ 40 years with diagnosis of BPH, IPSS ≥13, Qmax of 4–15 ml/s in a total voided volume ≥ 150 ml. Patients had been treated previously for BPH, diagnosed with prostate cancer, bladder cancer or other progressive diseases that could cause LUTS; PVR > 200 ml.
Roehrborn et al. (2014) [22] tamsulosin plus dutasteride tamsulosin 1610 1611 Oral 48 0 .4mg + 0 .5mg/0 .4mg Patients ≥50 years of age with diagnosis of BPH, IPSS ≥12, PV ≥30 mL, serum PSA ≥1.5 ng/mL, and Qmax > 5 mL/s and ≤ 15 mL/s with a minimum voided volume ≥ 125 mL. Serum PSA > 10 ng/mL, history of prostate cancer and previous prostatic surgery, history of AUR within 3 months before entry, 5ARI use within 6 months before entry, or use of α-blocker within 2 weeks before entry.
Roehrborn et al. (2015) [23] tamsulosin plus dutasteride tamsulosin 369 373 Oral 24 0 .4mg + 0 .5mg/0 .4mg Men aged ≥50 years with diagnosis of BPH and moderate LUTS, IPSS of 8–19, PV ≥30 cc by TRUS and serum PSA ≥1.5 ng/ml. Serum PSA > 10.0 ng/ml, history or evidence of prostate cancer and any current or prior treatment related to BPH.
Choi et al. (2016) [24] tamsulosin plus dutasteride tamsulosin 59 59 Oral 12 0 .2mg + 0 .5mg/0 .2mg Age ≥ 40, PV > 30 ml, IPSS ≥13, Qmax of 4–15 ml/s for a total voided volume of ≥150 ml, and no medical history relating to BPH during the previous 12 months. Patients had allergies to α-blocker, conditions other than BPH that could induce LUTS, progressive diseases, or severe hepatic or renal dysfunction, PVR > 200 ml or serum PSA > 4 ng/ml.
  1. BPH Benign Prostatic Hyperplasia, IPSS International Prostate Symptom Score, 5ARI 5-Alpha Reductase Inhibitor, Qmax maximum urine flow rate, PSA Prostate Specific Antigen, PV Prostate Volume, PVR Post-Void Residual, TRUS Transrectal ultrasonography, LUTS Lower Urinary Tract Symptoms, AUR Acute Urinary Retention